The technology known as CRISPR/Cas9 has been described as the 'holy grail' of genetic engineering, and has become the hottest research area because of its potential to cure many diseases by
Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
